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a b s t r a c t
Monoamine oxidase inhibition is an important therapeutic approach for various neurodegenerative dis-
orders. Reversible MAO inhibitors selectively targeting only one isoform possess substantial merit in
terms of safety, efficacy, and side effect profile. This study aimed to isolate the secondary metabolites
of Zanthoxylum flavum stems and evaluate their recombinant human MAO inhibition, antimicrobial,
and antiprotozoal activities. As a result, fourteen compounds were isolated and identified (nine of them
were reported from Z. flavum for the first time). Compound 3 (sesamin) exhibited potent selective MAO-B
inhibition (IC50 value of 1.45 ± 0.05 mM) which reported herein for the first time. Compound 2 showed
selective MAO-A inhibition activity, compound 5 exhibited good trypanocidal activity, and compound
7 displayed moderate antibacterial activity. The promising MAO-B inhibitory activity of sesamin pro-
voked us to further explore the kinetic properties, the binding mode, and the underlying mechanism
of MAO-B inhibition by this lignan. This detailed investigation substantiated a reversible binding and
mixed MAO-B catalytic function inhibition via sesamin (Ki: 0.473 ± 0.076 lM). Selectivity and reversibil-
ity of sesamin on MAO-B provide exciting prerequisites for further in vivo investigation to confirm its
therapeutic potentiality.
 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The interest of researchers in the discovery of selective MAO-A
or MAO-B inhibitors is steadily increasing. This interest stems from
the therapeutic potential of these inhibitors in neurodegenerative
diseases management (Carradori et al., 2018). Selective MAO-A
inhibitors have employed as effective antidepressants while sev-
eral MAO-B inhibitors are clinically used in Alzheimer’s and
Parkinson’s diseases therapy (Erdogan Orhan, 2016). The mito-
chondrial flavoprotein monoamine oxidases (MAOs), which are
expressed widely in both neuronal and non-neuronal tissues, are
responsible for the oxidative deamination of endogenous as well
as exogenous amines. Their two isoforms have different tissue dis-
tributions, substrate preference, and inhibitor specificity (Yildiz
et al., 2014). Non-selective and irreversible MAO inhibition is
accompanied by a hypertensive crisis risk after ingestion of dietary
tyramine, while selective MAO-B or MAO-A inhibitors are free from
this potential threat (Di Stefano et al., 2013). Therefore, much effort
has been devoted to finding new natural or synthetic selective
MAO inhibitors. Prolonged therapy with the clinically used irre-
versible MAO-B inhibitors has demonstrated undesirable effects
that evoking the urgent need for the discovery of reversible alter-
natives (Erdogan Orhan, 2016; Park et al., 2019). Park et al., 2019
developed a new reversible MAO-B inhibitor that efficiently lower-
ing increased GABA levels in Alzheimer’s patients and conse-
quently avoiding shortcomings of long-term treatment with
current irreversible ones.
Various medicinal properties have been reported from several
Zanthoxylum species (Rutaceae), including cytotoxic, hepatoprotec-
tive, antipyretic, diuretic, antioxidant, and tooth care (Nooreen
et al., 2019; Ross et al., 2008, 2006). Z. flavum Vahl, a rich source
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of coumarins, alkaloids, and lignans, is an evergreen tree found in
Cuba, Jamaica, Bahamas, Hispaniola, Bermuda, Lower Florida Keys,
and Puerto Rico. This plant has shown to possess antioxidant, cyto-
toxic, and mild antimalarial activities (Ross et al., 2008, 2006).
Sesamin, a major lignan in Z. flavum, and its structurally-related
derivatives have been reported to possess multifarious
pharmacological activities encompassing anti-inflammatory, anti-
carcinogenic, hepatic fatty acid oxidation enhancing, immune-
modulatory, antihypertensive, and neuroprotective activities
(Pathak et al., 2019).
The present study demonstrates, for the first time, selective
reversible inhibition of MAO-B enzymatic activity by sesamin.
MAO-B activity and oxidative stress are major factors for the occur-
rence of many neurodegenerative conditions (Niedzielska et al.,
2016). Therefore, antioxidant and neuroprotective properties of
sesamin along with its MAO-B inhibitory activity will enhance its
potential efficacy. This conclusion should be confirmed through
further in vivo and clinical studies.
2. Materials and methods
2.1. General experimental procedures
The 1H, 13C, and 2D NMR spectra were recorded on a Varian
Mercury 400 MHz spectrometer, Bruker Avance DRX spectrometer
at 600 MHz (1H) and 150 MHz (13C) using TMS as an internal stan-
dard. The HR-ESI-MS were done using a Bruker Bioapex-FTMS with
electrospray ionization. Adsorbents for column Chromatography
including Diaion HP-20, Silica gel 60 F254 (0.2 mm, Merck), MN-
polyamide-SC-6, and SephadexTM LH-20. Human recombinant
MAO-A and -B were obtained from BD Biosciences. Clorgyline,
R-(-)-deprenyl hydrochloride, Kynuramine dihydrobromide,
phenelzine sulfate, 4-hydroxyquinoline, K2HPO4 buffer, and DMSO
were purchased from Sigma.
2.2. Plant material
Stems of Z. flavum were collected and identified in August 2003
from Montgomery Botanical Centre, Old culture Road region in
Florida by Dr. Charles L. Burnadt and a voucher specimen (518
Audubon, Oxford, MS-38655) has been deposited at his herbarium.
2.3. Extraction and isolation
Air-dried powdered stems (1.3 kg) were macerated at room
temperature with 70% MeOH repeatedly till exhaustion. A dry resi-
due (121.6 g) was obtained after the concentration of the com-
bined extracts under reduced pressure. A water suspension of the
crude extract was prepared and partitioning was performed using
hexane, chloroform, and ethyl acetate to give three main fractions
(F1-F3), respectively. Column chromatography CC (silica gel, 800 g,
3.5  150 cm) was used for the fractionation of F2 (22.98 g) eluted
with a gradient of hexane-EtOAc of increasing polarities (95:5 to
90:10 to 85:15 to 80:20) to afford 8 sub-fractions (Fr. 1 to Fr. 8).
Fr. 1 (316 mg) was fractionated by CC (silica gel, 12 g,
1 20 cm) using a gradient of hexane-EtOAc (95:5 to 80:20) to fur-
nish compound 1 (10 mg). Fr. 2 (1 g) was subjected to CC (silica gel,
40 g, 2  60 cm) using hexane-EtOAc (85:15) then (70:30) to pro-
vide compound 2 (195 mg). Fr. 3 (2 g) was purified by CC (silica gel,
80 g, 1  100 cm) using hexane-EtOAc (7:3) to elute compound 3
(615 mg). Fr. 4 (750 mg) was separated using CC (silica gel, 30 g,
1  60 cm) eluted with hexane-EtOAc (7:3) affording compound
4 (86 mg). Fr. 6 (350 mg) was subjected to CC (silica gel, 12 g,
1  20 cm) eluted with hexane-EtOAc (4:6) to yield compound 5
(16.5 mg). Purification of Fr. 7 (460 mg) by CC (SephadexTM LH-
20, 50 g, 1  100 cm) using MeOH yielding compound 6
(7.9 mg). Diaion-HP20 was used for fractionation of the ethyl acet-
ate fraction F3 (11.3 g) starting the elution with distilled H2O then
MeOH. The methanol soluble fraction (10 g) was initially fraction-
ated via CC (silica gel, 400 g, 5  100 cm) using a gradient of DCM-
MeOH (98:2 to 7:3) to provide 236 fractions which grouped
according to TLC profile into 8 subfractions (E1 to E8). E1
(268.4 mg) was loaded onto (silica gel, 15 g, 1  30 cm) using
hexane-EtOAc (95:5) to give 10 subfractions from which subfrac-
tion 3 (37 mg) was further purified using CC (SephadexTM LH-20,
30 g, 1  80 cm) to give compound 7 (11.8 mg). E2 (600 mg)
was separated by CC (silica gel, 25 g, 1  30 cm) proceeding with
DCM-MeOH (98:2) as an elution system to afford compound 8
(6 mg). Fractionation of E4 (420 mg) by CC (SephadexTM LH-20,
50 g, 1  100 cm) using DCM-MeOH (1:1) affording compound 9
(92 mg) together with other promising subfractions which upon
further purification over silica gel using EtOAc-DCM-MeOH
(30:30:5.5) yield compound 10 (4.8 mg). Compound 11
(156.8 mg) was isolated via CC (silica gel, 50 g, 1.5  30 cm) from
E5 (1.2 g) using DCM-MeOH system (80:20 to 75: 25). E6 (2.6 g)
was fractionated by MN-polyamide SC-6 (250 g) starting the elu-
tion with 100% H2O then a gradient of H2O-MeOH till 100% MeOH
to obtain 8 subfractions which upon further purification via Sepha-
dexTM LH-20 afford compounds 12 (122.7 mg) and 13 (9.6 mg).
Compound 14 (77.2 mg) was obtained from E7 (490 mg) by CC
(SephadexTM LH-20, 50 g, 1  100 cm) using MeOH.
2.4. Antiprotozoal assay
Compounds 1–5, 7–9, and 11–14 were evaluated for their
antiprotozoal activities against Trypanosoma brucei brucei. The Ala-
mar Blue assay was used on cell cultures of Trypanosoma brucei try-
pomastigotes (Manda et al., 2014). Three concentrations of the
compounds ranging from 10  0.25 mg/mL were evaluated. The
dose-response curves with the aid of XLfit software were used
for computing IC50 and IC90 values which compared to DFMO as
a reference.
2.5. Antimicrobial assay
Compounds 1–5, 7–9, and 11–14 were evaluated for antimicro-
bial activity against Escherichia coli ATCC 35218, Pseudomonas
aeruginosa ATCC 27853, Mycobacterium intracellulare ATCC 23068,
Staphylococcus aureus ATCC 29213, methicillin-resistant S. aureus
ATCC 33591, Candida albicans ATCC 90028, C. glabrata ATCC
90030, C. krusei ATCC 6258, Aspergillus fumigatus ATCC 204305,
and Cryptococcus neoformans ATCC 90113. The compounds were
tested at 20, 10, 5.0, . . . 0.02 mg/mL. Ciprofloxacin was a positive
control for bacteria and amphotericin B was a positive control for
fungi (Bharate et al., 2007).
2.6. Monoamine oxidases (MAO-A/-B) inhibition assay
The kynuramine oxidative deamination assay was utilized to
evaluate the monoamine oxidases inhibitory effects of compounds
1–4, 7, 9 and 12–14 at concentrations of 0.001–100 lM for MAO-A
and 0.01–100 lM for MAO-B (Chaurasiya et al., 2016). The assay is
based on tracking and monitoring the MAO catalyzed conversion of
kynuramine to 4-hydroxy quinolone fluorometrically. The condi-
tions of the assay were optimized following the previously pub-
lished procedure (Larit et al., 2018). The oxidized fluorescent
product of kynuramine (4-hydroxyquinoline) was assessed at kem
380 nm and kex 320 nm following the published procedure using
the SoftMax Pro program (Parikh et al., 2002). The standard inhibi-
tors phenelzine, clorgyline, and deprenyl were used at a concentra-
tion range of 0.001 lM to 100 lMwith the aid of XL-Fit software.
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2.7. MAO-B kinetics inhibition mechanism with sesamin
The determination of the MAO-B inhibition constant (Ki) by
sesamin was carried out through enzymatic assays at different
kynuramine concentrations ranging from 1.90 to 500 lM and con-
fined sesamin concentrations. Two concentrations of the inhibitor,
one lower and another one higher than its IC50 value along with a
blank set (in absence of the inhibitor) were assayed to establish Km
and Vmax values of sesamin. The findings were carefully examined
for the inhibition category either competitive, uncompetitive, or
mixed type (Chaurasiya et al., 2016; Pandey et al., 2018). The
results were plotted as double reciprocal Lineweaver-Burk plots
and the kinetic parameters Km, Vmax, and Ki (inhibition/binding
affinity) were estimated via SigmaPlot 13.0 and the Enzyme-
Kinetics module applying the Michaelis-Menten equation.
2.8. Investigation of sesamin’s binding behavior with MAO-B
The sesamin’s binding behavior with human MAO-B recombi-
nant enzyme was studied through enzyme-inhibitor complex dis-
sociation by equilibrium dialysis (Chaurasiya et al., 2017).
Recombinant human MAO-B (50 lg/mL protein) incubated with
sesamin (15.0 lM) in an enzyme incubation mixture of 1 mL buf-
fered at pH 7.4 using 100 mM potassium phosphate. Following a
20 min incubation of the reaction mixture at 37 C, the reaction
was terminated by chilling on ice. Overnight dialysis of the formed
complex mixture was carried out against potassium phosphate
buffer at 4 C for approximately 14–16 h (replacing the buffer three
times). The difference between the catalytic activities of the human
MAO-B prior to and following the dialysis process was analyzed. A
parallel identical procedure was run for the enzyme control (in
absence of the inhibitor) along with the standard inhibitors depre-
nyl (a selective irreversible MAO-B inhibitor) and phenelzine (a
non-selective irreversible inhibitor).
3. Results and discussion
3.1. Identification of phytochemicals
The identification of the isolates was based on their spectroscopic
analyses interpretation (MS, 1D, and 2D NMR), compared with the
corresponding published data in the literature. The isolated com-
pounds were identified as lupeol (1) (Jamal et al., 2008), isoimpera-
torin (2) (Ross et al., 2008), sesamin (3) (Ross et al., 2008),
bergapten (4) (Ross et al., 2008), oxypeceudanin hydrate (5)
(Shalaby et al., 2014), cubebin (6) (Matsuda et al., 2004), imperatorin
(7) (Shalaby et al., 2014), pabulenol (8) (Shalaby et al., 2014), 4-
hydroxy-2-methoxyphenyl-6-O-syringyl-b-ᴅ-glucopyranoside (9)
(Bai et al., 2012), 5, 6, 3ʹ-trihydroxy-3, 7, 40-trimethoxyflavone-6-O-
b-ᴅ-glucopyranoside (10) (Bohm and Collins, 1979), marmesinin
(11) (Kitajima et al., 1998), isorutarin (12) (Sharma et al., 1979), oxy-
peucedanin hydrate 300-O-b-ᴅ-glucopyranoside (13) (Razavi et al.,
2008), and 5, 40-dihydroxy-30-methoxyflavanone-7- (600-O-a-ʟ-
rhamnopyranosyl)-b-ᴅ-glucopyranoside (14) (Gohari et al., 2012).
This study reveals the presence of compounds 5, 6, 8–14 in Z. flavum
for the first time. Coumarins, lignans, and flavonoids are of common
occurrence in the genus Zanthoxylum and the chemotaxonomic sig-
nificance of their accumulation within the genus is undeniable.
Therefore, the isolated compounds from the plant under study
greatly support its chemotaxonomy.
3.2. Determination of MAO-A and -B inhibitory effects
This study investigated the in vitro inhibitory effects of sesamin
and other isolated compounds on monoamine oxidases (MAOs)
catalytic activities (Table 1). Sesamin exhibited maximal selective
potency of MAO-B inhibition. Also, compound 2 showed selective
MAO-A inhibition activity. Considering the relevant neuroprotec-
tive and antioxidant effects of sesamin through attenuation of
oxidative stress, boosting the potential therapeutic value of sesa-
min in oxidative stress associated conditions is expected (Ahmad
et al., 2016).
3.3. Evaluation of MAO-B inhibition kinetic mechanism by sesamin
Analysis of the obtained data involving Ki, Km, and Vmax values
of sesamin represented in Table 2 and Fig. 1 indicated that sesamin
inhibited the catalytic function of MAO-B through a mixed manner
which allowed binding of sesamin in the active catalytic site or an
allosteric site on the enzyme, whether or not kynuramine has
already been bound, with different affinities for these two binding
sites.
3.4. Study of sesamin’s binding behavior with MAO-B
The equilibrium dialysis assay is based on incubating the
recombinant enzyme protein with high inhibitor concentrations
followed by comprehensive dialysis of the produced complex to
provide important information concerning the nature of the sesa-
min binding with the enzyme based on the reconstituted propor-
tion of the protein catalytic activity. Almost complete
inactivation of the enzyme was achieved upon incubation however
over 90% of functional recovery of the enzyme was recorded from
the enzyme-sesamin incubation mixture next to the overnight
dialysis. The blank reaction which was done on the recombinant
human MAO-B protein incubated without the inhibitor lost about
Table 1





1 (lupeol, C30H50O) na na
2 (isoimperatorin, C16H14O4) 6.98 ± 0.29 na
3 (sesamin, C20H18O6) na 1.45 ± 0.05
4 (bergapten, C12H8O4) 4.43 ± 0.15 8.85 ± 1.17




na 85.69 ± 7.77
11 (marmesinin, C20H24O9) na na
12 (isorutarin, C20H24O10) 33.20 ± 1.23 75.52 ± 4.29








Phenelzine 0.221 ± 0.009 0.131 ± 0.023
Clorgyline 0.0075 ± 0.0002 –
Deprenyl – 0.049 ± 0.003
* The IC50 values computed from the dose response inhibition curves are
mean ± SD of triplicate observations.na, not active at 100lM.
Table 2
Inhibition/binding affinity constants (Ki) values for inhibition of recombinant human
MAO-B by sesamin, phenelzine, and deprenyl.
Compounds Monoamine oxidase-B
Ki (mM)* Type of Inhibition
Sesamin 0.4730 ± 0.0760 Mixed/Reversible
Phenelzine (ref.) 0.0616 ± 0.0062 Mixed/Irreversible
Deprenyl (ref.) 0.0128 ± 0.0020 Mixed/Irreversible
* Values are mean ± SD of triplicate experiments.
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>5% of the enzymatic activity during overnight dialysis. Analogous
treatment of the enzyme with deprenyl and phenelzine also
showed irreversible inhibition/binding with the human MAO-B
protein (Chaurasiya et al., 2017; Pandey et al., 2018). These obser-
vations clearly indicated the dialyzable nature of the enzyme-
sesamin complexes. Thus, MAO-B enzyme is reversibly inactivated
via this new interesting inhibitor (Fig. 2). Considering the previ-
ously reported pharmacokinetic properties of sesamin, which
Fig. 1. Kinetic characteristics of recombinant human MAO-B inhibition with [A] phenelzine, [B] deprenyl and [C] sesamin. [V = nmoles/min/mg protein and S = substrate
kynuramine concentration (lM)].
Fig. 2. Analysis of the nature of binding of sesamin with recombinant human MAO-B by recovery of the catalytic activity of the enzyme after dialysis dissociation. [Each bar
shows mean ± SD of triplicate values].
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reveal its efficient absorption and wide distribution mainly in liver
and kidney as a metabolic form, sesamin may serve as a safer alter-
native to the classical irreversible inhibitors (Tomimori et al.,
2017).
3.5. Antimicrobial and antiprotozoal activities
Compound 5 showed good trypanocidal activity against
Trypanosoma brucei with IC50 and IC90 values of 5.75 and 6.78 mg/
mL, respectively compared to the positive control, DFMO with
IC50 and IC90 values of 3.59 and 8.09 lg/mL, respectively. Com-
pound 7 showed good antibacterial activity against M. intercellare
with an IC50 of 10.96 mg/mL compared to the positive control cipro-
floxacin (IC50 value of 0.399 mg/mL).
4. Concluding remarks and future perspective
Fourteen compounds were isolated from Z. flavum stems. Nota-
bly, compounds 5, 6, 8–14 were obtained from Z. flavum for the
first time. Compound 3 (sesamin) was the most active as MAO-B
selective inhibitor with an IC50 value of 1.45 ± 0.05 mM (Ki value
of 0.473 ± 0.076 lM) through a mixed enzyme blockade mecha-
nism. The reversible inactivation of MAO-B via sesamin was exper-
imentally confirmed. A properly designed in vivo studies and
clinical application of sesamin should be conducted. Additionally,
structure-activity relationship studies that comparing sesamin
with its analogues and derivatives worth careful examination to
determine the essential functional groups conferring the desired
activity of sesamin, unlock the therapeutic potentiality of these
structurally-related candidates and may illuminate more active
drugs that possess improved pharmaceutical characteristics.
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